2′Fluoro Modification Differentially Modulates the Ability of RNAs to Activate Pattern Recognition Receptors

Nucleic Acid Therapeutics

Volumn 26, Issue 3, 2016, Pages 173-182

  Lee, Youngju ^a   Urban, Johannes H ^a   Xu, Li ^a   Sullenger, Bruce A ^a   Lee, Jaewoo ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2'FLUORO PYRIMIDINE; APTAMER; BETA INTERFERON; CASPASE 7; CASPASE 9; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; INTERLEUKIN 6; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE R; PYRIMIDINE DERIVATIVE; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; STAUROSPORINE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; 2'FLUORO-2'-DEOXYURIDINE; CYTOKINE; FLOXURIDINE; TLR3 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPORATION; GENE KNOCKDOWN; GENETIC TRANSFECTION; HEPATITIS C VIRUS; HUH-7.5 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INNATE IMMUNITY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA STRUCTURE; SIGNAL TRANSDUCTION; WM266-4 CELL LINE; BIOSYNTHESIS; CHEMISTRY; CONFORMATION; DRUG EFFECTS; GENE EXPRESSION REGULATION;

CELL DEATH; CYTOKINES; FLOXURIDINE; GENE EXPRESSION REGULATION; HUMANS; NUCLEIC ACID CONFORMATION; RECEPTORS, PATTERN RECOGNITION; RNA; TOLL-LIKE RECEPTOR 3;

EID: 84993986490     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2015.0575     Document Type: Article

References (55)

1. Kubowicz P, D Zelaszczyk and E Pekala. (2013). RNAi in clinical studies. Curr Med Chem 20:1801-1816.
2. Sundaram P, H Kurniawan, ME Byrne and J Wower. (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48:259-271.
3. Lee J, CM Dollins, D Boczkowski, BA Sullenger and S Nair. (2008). Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. Immunology 125:229-240.
4. Lee J, M Fassnacht, S Nair, D Boczkowski and E Gilboa. (2005). Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-Associated fibroblasts. Cancer Res 65:11156-11163.
5. Schlaeger TM, L Daheron, TR Brickler, S Entwisle, K Chan, A Cianci, A DeVine, A Ettenger, K Fitzgerald, et al. (2015). A comparison of non-integrating reprogramming methods. Nat Biotechnol 33:58-63.
6. Olejniczak M, K Polak, P Galka-Marciniak and WJ Krzyzosiak. (2011). Recent advances in understanding of the immunological off-Target effects of siRNA. Curr Gene Ther 11:532-543.
7. Angel M and MF Yanik. (2010). Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One 5:e11756.
8. Vacchelli E, A Eggermont, C Sautes-Fridman, J Galon, L Zitvogel, G Kroemer and L Galluzzi. (2013). Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2:e25238.
9. Besch R, H Poeck, T Hohenauer, D Senft, G Hacker, C Berking, VHornung, S Endres, TRuzicka, SRothenfusser and GHartmann. (2009). Proapoptotic signaling induced byRIG-I andMDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest 119:2399-2411.
10. Tormo D, A Checinska, D Alonso-Curbelo, E Perez-Guijarro, E Canon, E Riveiro-Falkenbach, TG Calvo, L Larribere, D Megias, et al. (2009). Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16:103-114.
11. Peng S, J Geng, R Sun, Z Tian and H Wei. (2009). Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 100:529-536.
12. Matsushima-Miyagi T, K Hatano, M Nomura, L Li-Wen, T Nishikawa, KSaga, TShimbo andYKaneda. (2012).TRAILand Noxa are selectively upregulated in prostate cancer cells downstream of the RIG-I/MAVS signaling pathway by nonreplicating Sendai virus particles. Clin Cancer Res 18:6271-6283.
13. Duewell P, A Steger, H Lohr, H Bourhis, H Hoelz, SV Kirchleitner, MR Stieg, S Grassmann, S Kobold, et al. (2014). RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8 T cells. Cell Death Differ 21:1825-1837.
14. Bhoopathi P, BA Quinn, Q Gui, XN Shen, SR Grossman, SK Das, D Sarkar, PB Fisher and L Emdad. (2014). Pancreatic cancer-specific cell death induced in vivo by cytoplasmicdelivered polyinosine-polycytidylic acid. Cancer Res 74: 6224-6235.
15. Ellermeier J, J Wei, P Duewell, S Hoves, MR Stieg, T Adunka, D Noerenberg, HJ Anders, D Mayr, et al. (2013). Therapeutic efficacy of bifunctional siRNA combining TGFbeta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 73:1709-1720.
16. Meng G, M Xia, C Xu, D Yuan, M Schnurr and J Wei. (2014). Multifunctional antitumor molecule 5-Triphosphate siRNA combining glutaminase silencing and RIG-I activation. Int J Cancer 134:1958-1971.
17. Lotze MT, HJ Zeh, A Rubartelli, LJ Sparvero, AA Amoscato, NR Washburn, ME Devera, X Liang, M Tor and T Billiar. (2007). The grateful dead: damage-Associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 220:60-81.
18. Yu M and SJ Levine. (2011). Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: key modulators of innate immune responses to double-stranded RNA viruses. Cytokine Growth Factor Rev 22:63-72.
19. Diebold SS, T Kaisho, H Hemmi, S Akira and C Reis e Sousa. (2004). Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529-1531.
20. Heil F, H Hemmi, H Hochrein, F Ampenberger, C Kirschning, S Akira, G Lipford, H Wagner and S Bauer. (2004). Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526-1529.
21. Song W, J Wang, Z Han, Y Zhang, H Zhang, Y Zhang, H Zhang, W Wang, J Chang, et al. (2015). Structural basis for specific recognition of single-stranded RNA by Toll-like receptor 13. Nat Struct Mol Biol 22:782-787.
22. Kawai T and S Akira. (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:637-650.
23. Sabroe I, LC Parker, SK Dower and MK Whyte. (2008). The role of TLR activation in inflammation. J Pathol 214: 126-135.
24. Kohlway A, D Luo, DC Rawling, SC Ding and AM Pyle. (2013). Defining the functional determinants for RNA surveillance by RIG-I. EMBO Rep 14:772-779.
25. Sioud M. (2006). Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: A central role for 2-hydroxyl uridines in immune responses. Eur J Immunol 36:1222-1230.
26. Robbins M, A Judge, L Liang, K McClintock, E Yaworski and I MacLachlan. (2007). 2-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther 15:1663-1669.
27. Sioud M. (2010). Development of TLR7/8 small RNA antagonists. Methods Mol Biol 629:387-394.
28. Warren L, PD Manos, T Ahfeldt, YH Loh, H Li, F Lau, W Ebina, PK Mandal, ZD Smith, et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618-630.
29. Rettig GR and MA Behlke. (2012). Progress toward in vivo use of siRNAs-II. Mol Ther 20:483-512.
30. Khairuddin N, MP Gantier, SJ Blake, SY Wu, MA Behlke, BR Williams and NA McMillan. (2012). siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 90:187-196.
31. Layzer JM and BA Sullenger. (2007). Simultaneous generation of aptamers to multiple gamma-carboxyglutamic acid proteins from a focused aptamer library using DeSELEX and convergent selection. Oligonucleotides 17:1-11.
32. Padilla R and R Sousa. (2002). A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res 30:e138.
33. Jelinek I, JN Leonard, GE Price, KN Brown, A Meyer-Manlapat, PK Goldsmith, Y Wang, D Venzon, SL Epstein and DM Segal. (2011). TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell crosspresentation, CTL responses, and antiviral protection. J Immunol 186:2422-2429.
34. Forsbach A, JG Nemorin, C Montino, C Muller, U Samulowitz, AP Vicari, M Jurk, GK Mutwiri, AM Krieg, GB Lipford and J Vollmer. (2008). Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses. J Immunol 180:3729-3738.
35. Zhang YL, YJ Guo, L Bin and SH Sun. (2009). Hepatitis C virus single-stranded RNA induces innate immunity via Toll-like receptor 7. J Hepatol 51:29-38.
36. Sumpter R, Jr., YM Loo, E Foy, K Li, M Yoneyama, T Fujita, SM Lemon and M Gale, Jr. (2005). Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 79:2689-2699.
37. Song KM, S Lee and C Ban. (2012). Aptamers and their biological applications. Sensors (Basel) 12:612-631.
38. Longley DB, DP Harkin and PG Johnston. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330-338.
39. Uzri D and L Gehrke. (2009). Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol 83:4174-4184.
40. Zust R, L Cervantes-Barragan, M Habjan, R Maier, BW Neuman, J Ziebuhr, KJ Szretter, SC Baker, W Barchet, et al. (2011). Ribose 2-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12:137-143.
41. Judge AD, G Bola, AC Lee and I MacLachlan. (2006). Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 13:494-505.
42. Hornung V, J Ellegast, S Kim, K Brzozka, A Jung, H Kato, H Poeck, S Akira, KK Conzelmann, et al. (2006). 5-Triphosphate RNA is the ligand for RIG-I. Science 314: 994-997.
43. Hwang SY, HY Sun, KH Lee, BH Oh, YJ Cha, BH Kim and JY Yoo. (2012). 5-Triphosphate-RNA-independent activation of RIG-I via RNA aptamer with enhanced antiviral activity. Nucleic Acids Res 40:2724-2733.
44. Nallagatla SR and PC Bevilacqua. (2008). Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14:1201-1213.
45. Wang Y, J Ludwig, C Schuberth, M Goldeck, M Schlee, H Li, S Juranek, G Sheng, R Micura, et al. (2010). Structural and functional insights into 5-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat Struct Mol Biol 17:781-787.
46. Manoharan M, A Akinc, RK Pandey, J Qin, P Hadwiger, M John, K Mills, K Charisse, MA Maier, et al. (2011). Unique gene-silencing and structural properties of 2-fluoro-modified siRNAs. Angew Chem Int Ed Engl 50:2284-2288.
47. Glas M, C Coch, D Trageser, J Dassler, M Simon, P Koch, J Mertens, T Quandel, R Gorris, et al. (2013). Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma. Stem Cells 31:1064-1074.
48. Ishibashi O, MM Ali, SS Luo, T Ohba, H Katabuchi, T Takeshita and T Takizawa. (2011). Short RNA duplexes elicit RIG-I-mediated apoptosis in a cell type-And lengthdependent manner. Sci Signal 4:ra74.
49. Avci-Adali M, H Steinle, T Michel, C Schlensak and HP Wendel. (2013). Potential capacity of aptamers to trigger immune activation in human blood. PLoS One 8:e68810.
50. Dassie JP, XY Liu, GS Thomas, RM Whitaker, KW Thiel, KR Stockdale, DK Meyerholz, AP McCaffrey, JO 2nd McNamara and PH Giangrande. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839-849.
51. Pastor F, D Kolonias, PH Giangrande and E Gilboa. (2010). Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 465:227-230.
52. Cheng YS and F Xu. (2011). Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 10:1219-1223.
53. Kariko K, H Ni, J Capodici, M Lamphier and D Weissman. (2004). mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279:12542-12550.
54. Lehmann SM, C Kruger, B Park, K Derkow, K Rosenberger, J Baumgart, T Trimbuch, G Eom, M Hinz, et al. (2012). An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 15:827-835.
55. Hornung V, M Guenthner-Biller, C Bourquin, A Ablasser, M Schlee, S Uematsu, A Noronha, M Manoharan, S Akira, et al. (2005). Sequence-specific potent induction of IFNalpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263-270.